ACTUATE THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney
SIGNATURES AND POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel M. Schmitt and Paul Lytle, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Name | Position | Date |
|---|---|---|
| /s/ Daniel M. Schmitt | President, Chief Executive Officer and Director (principal executive officer) | March 13, 2025 |
| Daniel M. Schmitt | ||
| /s/ Paul Lytle | Chief Financial Officer (principal financial and accounting officer) | March 13, 2025 |
| Paul Lytle | ||
| /s/ Aaron G. L. Fletcher | Director and Chairperson | March 13, 2025 |
| Aaron G.L. Fletcher, Ph.D. | ||
| /s/ Jason Keyes | Director | March 13, 2025 |
| Jason Keyes | ||
| /s/ Amy Ronneberg | Director | March 13, 2025 |
| Amy Ronneberg | ||
| /s/ Roger Sawhney | Director | March 13, 2025 |
| Roger Sawhney | ||
| /s/ Todd Thomson | Director | March 13, 2025 |
| Todd Thomson | ||
| /s/ Daniel Zabrowski | Director | March 13, 2025 |
| Daniel Zabrowski, Ph.D. | ||
ACTUATE THERAPEUTICS, INC.
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 173) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 170) | F-3 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-7 |
| Notes to the Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.